一般用医薬品における禁忌情報の実態及び製薬会社の意識調査 - 塩化リゾチーム含有製剤について -

木津純子、森ちはる。、荒川基記。、川本嘉子

共立薬科大学 〒105-8512 東京都港区芝公園1-5-30

(a現 放射線医学総合研究所, b現 日本大学薬学部薬理学研究室)

Status of information on contraindications for non-prescription drugs and a survey on pharmaceutical companies' awareness

- With respect to preparations containing lysozyme chloride -

Junko Kizu, Chiharu Mori^a, Motoki Arakawa^b, Yoshiko Kawamoto

Kyoritsu College of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan

(^aNational Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan

^bDepartment of Pharmacology College of Pharmacy, Nihon University,7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan)

(Received February 25, 2003) Accepted March 25, 2003)

Abstract :

Objective We investigated the status of information on contraindications for non-prescription drugs containing lysozyme chloride, which is contraindicated by patients with egg allergy, and pharmaceutical companies' awareness.

Methods Preparations containing lysozyme chloride were searched. In pharmaceutical companies that sold these preparations, we conducted a questionnaire survey regarding the presence or absence of described contraindication information, content of description, and future change/plan. **Results** One hundred and eighty-seven preparations were commercially available, and were manufactured by 76 companies. We obtained information on 125 preparations (195 standards) from 47 companies. In 87 standards, contraindication information could not be obtained unless a package box was opened. In 77 standards, contraindications were not described, but a sentence, "you should consult a physician or pharmaci st ", was printed. 13 companies considered these indications sufficient, with no changes needed.

Conclusion Since there are some non-prescription drugs containing lysozyme chloride showing no warning indications, it is necessary to provide appropriate information for patients with egg allergy.

Keyword: lysozyme chloride, non-prescription drug, egg allergy, contraindication information, pharmaceutical company